Targeting Hsp90 in urothelial carcinoma

Oncotarget

Volumn 6, Issue 11, 2015, Pages 8454-8473

  Chehab, Mahmoud ^a   Caza, Tiffany ^a   Skotnicki, Kamil ^a   Landas, Steve ^a   Bratslavsky, Gennady ^a,b   Mollapour, Mehdi ^a,b   Bourboulia, Dimitra ^a,b  

^a State University of New York Upstate Medical University: College of Medicine   (United States)

^b SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

Author keywords

Bladder cancer treatments; Heat shock protein 90; Hsp90 inhibitors; Pathogenesis; Urothelial carcinoma

Indexed keywords

2',3' DIDEOXY 5 FLUOROCYTIDINE; AFATINIB; BCG VACCINE; BEVACIZUMAB; CABOZANTINIB; CARBOPLATIN; CHAPERONE; CISPLATIN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; DOCETAXEL; DOVITINIB; DOXORUBICIN; ERIBULIN; ERLOTINIB; FALIMAREV; FIBROBLAST GROWTH FACTOR RECEPTOR 3; GANETESPIB; GEMCITABINE; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; LENALIDOMIDE; MARGETUXIMAB; METHOTREXATE; RAPAMYCIN; ROMIDEPSIN; TANESPIMYCIN; TETRAHYDROURIDINE; UNINDEXED DRUG; VELIPARIB; VINBLASTINE; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; NEW DRUG; PROTEIN KINASE INHIBITOR; TUMOR PROTEIN;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER CANCER; BLADDER CARCINOGENESIS; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER RESISTANCE; CELL CYCLE PROGRESSION; CHEMORADIOTHERAPY; COST OF ILLNESS; CYSTECTOMY; DNA REPAIR; DRUG APPROVAL; DRUG BINDING SITE; DRUG POTENTIATION; EPIGENETICS; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; INTRACELLULAR SIGNALING; METASTASIS; METASTASIS POTENTIAL; MOLECULAR PATHOLOGY; MOLECULARLY TARGETED THERAPY; MUSCLE INVASIVE BLADDER CANCER; NON MUSCLE INVASIVE BLADDER CANCER; NONHUMAN; PROTEIN EXPRESSION; PROTEIN TARGETING; RADIOSENSITIZATION; TRANSCRIPTION REGULATION; TRANSITIONAL CELL CARCINOMA; TRANSURETHRAL RESECTION; ADJUVANT CHEMOTHERAPY; ANTAGONISTS AND INHIBITORS; APOPTOSIS; BIOLOGICAL MODEL; CARCINOMA, TRANSITIONAL CELL; CELL CYCLE; CELL DIVISION; CELL TRANSFORMATION; CHEMISTRY; CLINICAL TRIAL (TOPIC); DRUG EFFECTS; DRUG RESISTANCE; GENETIC TRANSCRIPTION; HISTONE CODE; METABOLISM; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION; SMOOTH MUSCLE; TUMOR INVASION; UROLOGIC NEOPLASMS;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BCG VACCINE; CARCINOMA, TRANSITIONAL CELL; CELL CYCLE; CELL DIVISION; CELL TRANSFORMATION, NEOPLASTIC; CHEMORADIOTHERAPY; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; CYSTECTOMY; DRUG RESISTANCE, NEOPLASM; DRUGS, INVESTIGATIONAL; HISTONE CODE; HSP90 HEAT-SHOCK PROTEINS; HUMANS; MODELS, BIOLOGICAL; MOLECULAR TARGETED THERAPY; MUSCLE, SMOOTH; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; PROTEIN KINASE INHIBITORS; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC; UROLOGIC NEOPLASMS;

EID: 84928708914     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3502     Document Type: Article

References (195)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics. CA Cancer Journal for Clinicians. 2014; 64:9-29.
2. Ploeg M, Aben KK, Kiemeney LA. The present and future burden of urinary bladder cancer in the world. World journal of urology. 2009; 27:289-293.
3. Fleshner NE, Herr HW, Stewart AK, Murphy GP, Mettlin C, Menck HR. The National Cancer Data Base report on bladder carcinoma. Cancer. 1996; 78:1505-1513.
4. Lucca I, Fajkovic H, Klatte T. Sex steroids and gender differences in nonmuscle invasive bladder cancer. Current opinion in urology. 2014.
5. Chang C, Lee SO, Yeh S, Chang TM. Androgen receptor (AR) differential roles in hormone-related tumors including prostate, bladder, kidney, lung, breast and liver. Oncogene. 2014; 33:3225-3234.
6. Svatek RS, Hollenbeck BK, Holmang S, Lee R, Kim SP, Stenzl A, Lotan Y. The economics of bladder cancer: costs and considerations of caring for this disease. European urology. 2014; 66:253-262.
7. Cancer IAfRo. (2004). World Health Organization classification of tumors: tumors of the urinary system and male genital organs. Chapter 2: tumors of the urinary system. In: Eble JS, G, Epstein JI, Sesterhemm IA, ed. (Lyon: IARC Press), pp. 86-154.
8. Van Hemelrijck M, Feller A, Garmo H, Valeri F, Korol D, Dehler S, Rohrmann S. Incidence of second malignancies for prostate cancer. PloS one. 2014; 9.
9. Kaufman DS, Shipley WU, Feldman AS. Bladder cancer. Lancet. 2009; 374:239-249.
10. Richter S, Sridhar SS. New directions for biologic targets in urothelial carcinoma. Molecular Cancer Therapeutics. 2012; 11:1226-1235.
11. van der Heijden AG, Witjes JA. Recurrence, Progression, and Follow-Up in Non-Muscle-Invasive Bladder Cancer. European Urology. 2009; 8:556-562.
12. Crivelli JJ, Xylinas E, Kluth LA, Rieken M, Rink M, Shariat SF. Effect of smoking on outcomes of urothelial carcinoma: A systematic review of the literature. European urology. 2014; 65:742-754.
13. Zeegers MP, Tan FE, Dorant E, van Den Brandt PA. The impact of characteristics of cigarette smoking on urinary tract cancer risk: a meta-analysis of epidemiologic studies. Cancer. 2000; 89:630-639.
14. Brait M, Munari E, LeBron C, Noordhuis MG, Begum S, Michailidi C, Gonzalez-Roibon N, Maldonado L, Sen T, Guerrero-Preston R, Cope L, Parrella P, Fazio VM, Ha PK, Netto GJ, Sidransky D, et al. Genome-wide methylation profiling and the PI3K-AKT pathway analysis associated with smoking in urothelial cell carcinoma. Cell Cycle. 2013; 12:1058-1070.
15. Simonis K, Shariat SF, Rink M. Urothelial Cancer Working Group of the Young Academic Urologists Working Party of the European Association of U. Smoking and smoking cessation effects on oncological outcomes in nonmuscle invasive bladder cancer. Current opinion in urology. 2014; 24:492-499.
16. Johansson SL, Cohen SM. Epidemiology and etiology of bladder cancer. Seminars in surgical oncology. 1997; 13:291-298.
17. Knowles MA, Hurst CD. Molecular biology of bladder cancer:new insights into pathogenesis and clinical diversity. Nature reviews Cancer. 2015; 15:25-41.
18. Netto GJ. Molecular biomarkers in urothelial carcinoma of the bladder: are we there yet? Nature reviews Urology. 2012; 9:41-51.
19. Zhou H, Huang HY, Shapiro E, Lepor H, Huang WC, Mohammadi M, Mohr I, Tang MS, Huang C, Wu XR. Urothelial tumor initiation requires deregulation of multiple signaling pathways: implications in target-based therapies. Carcinogenesis. 2012; 33:770-780.
20. Ischia J, So AI. The role of heat shock proteins in bladder cancer. Nature Reviews Urology. 2013; 10:386-395.
21. Trepel J, Mollapour M, Giaccone G, Neckers L. Targeting the dynamic HSP90 complex in cancer. Nature Reviews Cancer. 2010; 10:537-549.
22. Jhaveri K, Taldone T, Modi S, Chiosis G. Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers. Biochimica et Biophysica Acta -Molecular Cell Research. 2012; 1823:742-755.
23. Neckers L, Workman P. Hsp90 molecular chaperone inhibitors:Are we there yet? Clinical Cancer Research. 2012; 18:64-76.
24. Jhaveri K, Ochiana SO, Dunphy MPS, Gerecitano JF, Corben AD, Peter RI, Janjigian YY, Gomes-Dagama EM, Koren Iii J, Modi S, Chiosis G. Heat shock protein 90 inhibitors in the treatment of cancer: Current status and future directions. Expert Opinion on Investigational Drugs. 2014; 23:611-628.
25. Miyata Y, Nakamoto H, Neckers L. The therapeutic target Hsp90 and cancer hallmarks. Current Pharmaceutical Design. 2013; 19:347-365.
26. Hong DS, Banerji U, Tavana B, George GC, Aaron J, Kurzrock R. Targeting the molecular chaperone heat shock protein 90 (HSP90): Lessons learned and future directions. Cancer Treatment Reviews. 2013; 39:375-387.
27. Ali MMU, Mark Roe S, Vaughan CK, Meyer P, Panaretou B, Piper PW, Prodromou C, Pearl LH. Crystal structure of an Hsp90-nucleotide-p23/Sba1 closed chaperone complex. Nature. 2006; 440:1013-1017.
28. Prodromou C, Pearl LH. Structure and functional relationships of Hsp90. Curr Cancer Drug Targets. 2003; 3:301-323.
29. Ratzke C, Mickler M, Hellenkamp B, Buchner J, Hugel T. Dynamics of heat shock protein 90 C-terminal dimerization is an important part of its conformational cycle. Proceedings of the National Academy of Sciences of the United States of America. 2010; 107:16101-16106.
30. Lavery LA, Partridge JR, Ramelot TA, Elnatan D, Kennedy MA, Agard DA. Structural Asymmetry in the Closed State of Mitochondrial Hsp90 (TRAP1) Supports a Two-Step ATP Hydrolysis Mechanism. Molecular Cell. 2014; 53:330-343.
31. Shiau AK, Harris SF, Southworth DR, Agard DA. Structural Analysis of E. coli hsp90 Reveals Dramatic Nucleotide-Dependent Conformational Rearrangements. Cell. 2006; 127:329-340.
32. Stebbins CE, Russo AA, Schneider C, Rosen N, Hartl FU, Pavletich NP. Crystal structure of an Hsp90-geldanamycin complex: Targeting of a protein chaperone by an antitumor agent. Cell. 1997; 89:239-250.
33. Hainzl O, Lapina MC, Buchner J, Richter K. The charged linker region is an important regulator of Hsp90 function. Journal of Biological Chemistry. 2009; 284:22559-22567.
34. Hessling M, Richter K, Buchner J. Dissection of the ATPinduced conformational cycle of the molecular chaperone Hsp90. Nature Structural and Molecular Biology. 2009; 16:287-293.
35. Mickler M, Hessling M, Ratzke C, Buchner J, Hugel T. The large conformational changes of Hsp90 are only weakly coupled to ATP hydrolysis. Nature Structural and Molecular Biology. 2009; 16:281-286.
36. Retzlaff M, Stahl M, Eberl HC, Lagleder S, Beck J, Kessler H, Buchner J. Hsp90 is regulated by a switch point in the C-terminal domain. EMBO Reports. 2009; 10:1147-1153.
37. Tsutsumi S, Mollapour M, Graf C, Lee CT, Scroggins BT, Xu W, Haslerova L, Hessling M, Konstantinova AA, Trepel JB, Panaretou B, Buchner J, Mayer MP, Prodromou C, Neckers L. Hsp90 charged-linker truncation reverses the functional consequences of weakened hydrophobic contacts in the N domain. Nature Structural and Molecular Biology. 2009; 16:1141-1147.
38. Panaretou B, Prodromou C, Roe SM, O'Brien R, Ladbury JE, Piper PW, Pearl LH. ATP binding and hydrolysis are essential to the function of the Hsp90 molecular chaperone in vivo. EMBO Journal. 1998; 17:4829-4836.
39. Walton-Diaz A, Khan S, Bourboulia D, Trepel JB, Neckers L, Mollapour M. Contributions of co-chaperones and post-translational modifications towards Hsp90 drug sensitivity. Future Medicinal Chemistry. 2013; 5:1059-1071.
40. Li J, Richter K, Buchner J. Mixed Hsp90-cochaperone complexes are important for the progression of the reaction cycle. Nature Structural and Molecular Biology. 2011; 18:61-67.
41. Soroka J, Wandinger SK, Mäusbacher N, Schreiber T, Richter K, Daub H, Buchner J. Conformational Switching of the Molecular Chaperone Hsp90 via Regulated Phosphorylation. Molecular Cell. 2012; 45:517-528.
42. Mollapour M, Bourboulia D, Beebe K, Woodford MR, Polier S, Hoang A, Chelluri R, Li Y, Guo A, Lee MJ, Fotooh-Abadi E, Khan S, Prince T, Miyajima N, Yoshida S, Tsutsumi S, et al. Asymmetric Hsp90 N Domain SUMOylation Recruits Aha1 and ATP-Competitive Inhibitors. Molecular Cell. 2014; 53:317-329.
43. Mollapour M, Tsutsumi S, Donnelly AC, Beebe K, Tokita MJ, Lee MJ, Lee S, Morra G, Bourboulia D, Scroggins BT, Colombo G, Blagg BS, Panaretou B, Stetler-Stevenson WG, Trepel JB, Piper PW, et al. Swe1Wee1-Dependent Tyrosine Phosphorylation of Hsp90 Regulates Distinct Facets of Chaperone Function. Molecular Cell. 2010; 37:333-343.
44. Mollapour M, Tsutsumi S, Neckers L. Hsp0 phosphorylation, Wee1 and the cell cycle. Cell Cycle. 2010; 9:2310-2316.
45. Roe SM, Prodromou C, O'Brien R, Ladbury JE, Piper PW, Pearl LH. Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin. Journal of Medicinal Chemistry. 1999; 42:260-266.
46. Xu W, Mimnaugh EG, Kim JS, Trepel JB, Neckers LM. Hsp90, not grp94, regulates the intracellular trafficking and stability of nascent ErbB2. Cell Stress and Chaperones. 2002; 7:91-96.
47. Caplan AJ, Mandal AK, Theodoraki MA. Molecular chaperones and protein kinase quality control. Trends in Cell Biology. 2007; 17:87-92.
48. Garcia-Carbonero R, Carnero A, Paz-Ares L. Inhibition of HSP90 molecular chaperones: Moving into the clinic. The Lancet Oncology. 2013; 14:e358-e369.
49. Yamaki H, Nakajima M, Shimotohno KW, Tanaka N. Molecular basis for the actions of Hsp90 inhibitors and cancer therapy. The Journal of antibiotics. 2011; 64:635-644.
50. Park SJ, Kostic M, Dyson HJ. Dynamic Interaction of Hsp90 with Its Client Protein p53. Journal of molecular biology. 2011; 411:158-173.
51. Sidera K, Gaitanou M, Stellas D, Matsas R, Patsavoudi E. A critical role for HSP90 in cancer cell invasion involves interaction with the extracellular domain of HER-2. The Journal of biological chemistry. 2008; 283:2031-2041.
52. Gerbin CS, Landgraf R. Geldanamycin selectively targets the nascent form of ERBB3 for degradation. Cell stress & chaperones. 2010; 15:529-544.
53. Prince T, Sun L, Matts RL. Cdk2: a genuine protein kinase client of Hsp90 and Cdc37. Biochemistry. 2005; 44:15287-15295.
54. Stepanova L, Leng X, Parker SB, Harper JW. Mammalian p50Cdc37 is a protein kinase-targeting subunit of Hsp90 that binds and stabilizes Cdk4. Genes & development. 1996; 10:1491-1502.
55. Mosser DD, Morimoto RI. Molecular chaperones and the stress of oncogenesis. Oncogene. 2004; 23:2907-2918.
56. Basso AD, Solit DB, Chiosis G, Giri B, Tsichlis P, Rosen N. Akt forms an intracellular complex with heat shock protein 90 (Hsp90) and Cdc37 and is destabilized by inhibitors of Hsp90 function. The Journal of biological chemistry. 2002; 277:39858-39866.
57. Ahsan A, Ramanand SG, Whitehead C, Hiniker SM, Rehemtulla A, Pratt WB, Jolly S, Gouveia C, Truong K, Van Waes C, Ray D, Lawrence TS, Nyati MK. Wild-type EGFR is stabilized by direct interaction with HSP90 in cancer cells and tumors. Neoplasia. 2012; 14:670-677.
58. Laederich MB, Degnin CR, Lunstrum GP, Holden P, Horton WA. Fibroblast growth factor receptor 3 (FGFR3) is a strong heat shock protein 90 (Hsp90) client: implications for therapeutic manipulation. The Journal of biological chemistry. 2011; 286:19597-19604.
59. Sawai A, Chandarlapaty S, Greulich H, Gonen M, Ye Q, Arteaga CL, Sellers W, Rosen N, Solit DB. Inhibition of Hsp90 down-regulates mutant epidermal growth factor receptor (EGFR) expression and sensitizes EGFR mutant tumors to paclitaxel. Cancer research. 2008; 68:589-596.
60. Weinstein JN, Akbani R, Broom BM, Wang W, Verhaak RGW, McConkey D, Lerner S, Morgan M, Creighton CJ, Smith C, Cherniack AD, Kim J, Pedamallu CS, Noble MS, Al-Ahmadie HA, Reuter VE, et al. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature. 2014; 507:315-322.
61. Prinsloo E, Kramer AH, Edkins AL, Blatch GL. STAT3 interacts directly with Hsp90. IUBMB life. 2012; 64:266-273.
62. Wang SA, Chuang JY, Yeh SH, Wang YT, Liu YW, Chang WC, Hung JJ. Heat shock protein 90 is important for Sp1 stability during mitosis. Journal of molecular biology. 2009; 387:1106-1119.
63. Abat D, Demirhan O, Inandiklioglu N, Tunc E, Erdogan S, Tastemir D, Uslu IN, Tansug Z. Genetic alterations of chromosomes, p53 and p16 genes in low- and high-grade bladder cancer. Oncology Letters. 2014; 8:25-32.
64. di Martino E, Tomlinson DC, Knowles MA. A Decade of FGF Receptor Research in Bladder Cancer: Past, Present, and Future Challenges. Advances in urology. 2012; 2012:429213.
65. Williams SV, Hurst CD, Knowles MA. Oncogenic FGFR3 gene fusions in bladder cancer. Human molecular genetics. 2013; 22:795-803.
66. Hagn F, Lagleder S, Retzlaff M, Rohrberg J, Demmer O, Richter K, Buchner J, Kessler H. Structural analysis of the interaction between Hsp90 and the tumor suppressor protein p53. Nature structural & molecular biology. 2011; 18:1086-1093.
67. Peng Y, Chen L, Li C, Lu W, Chen J. Inhibition of MDM2 by hsp90 contributes to mutant p53 stabilization. The Journal of biological chemistry. 2001; 276:40583-40590.
68. He K, Zheng X, Zhang L, Yu J. Hsp90 inhibitors promote p53-dependent apoptosis through PUMA and bax. Molecular Cancer Therapeutics. 2013; 12:2559-2568.
69. Lin K, Rockliffe N, Johnson GG, Sherrington PD, Pettitt AR. Hsp90 inhibition has opposing effects on wild-type and mutant p53 and induces p21 expression and cytotoxicity irrespective of p53/ATM status in chronic lymphocytic leukaemia cells. Oncogene. 2008; 27:2445-2455.
70. Xu HJ, Cairns P, Hu SX, Knowles MA, Benedict WF. Loss of RB protein expression in primary bladder cancer correlates with loss of heterozygosity at the RB locus and tumor progression. International journal of cancer Journal international du cancer. 1993; 53:781-784.
71. Fletcher O, Easton D, Anderson K, Gilham C, Jay M, Peto J. Lifetime risks of common cancers among retinoblastoma survivors. Journal of the National Cancer Institute. 2004; 96:357-363.
72. Srethapakdi M, Liu F, Tavorath R, Rosen N. Inhibition of Hsp90 function by ansamycins causes retinoblastoma gene product-dependent G1 arrest. Cancer research. 2000; 60:3940-3946.
73. Yeager T, Stadler W, Belair C, Puthenveettil J, Olopade O, Reznikoff C. Increased p16 levels correlate with pRb alterations in human urothelial cells. Cancer research. 1995; 55:493-497.
74. Shariat SF, Tokunaga H, Zhou J, Kim J, Ayala GE, Benedict WF, Lerner SP. p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2004; 22:1014-1024.
75. Steinestel J, Cronauer MV, Muller J, Al Ghazal A, Skowronek P, Arndt A, Kraft K, Schrader M, Schrader AJ, Steinestel K. Overexpression of p16(INK4a) in urothelial carcinoma in situ is a marker for MAPK-mediated epithelial- mesenchymal transition but is not related to human papillomavirus infection. PloS one. 2013; 8:e65189.
76. Corral R, Lewinger JP, Van Den Berg D, Joshi AD, Yuan JM, Gago-Dominguez M, Cortessis VK, Pike MC, Conti DV, Thomas DC, Edlund CK, Gao YT, Xiang YB, Zhang W, Su YC, Stern MC. Comprehensive analyses of DNA repair pathways, smoking and bladder cancer risk in Los Angeles and Shanghai. International journal of cancer Journal international du cancer. 2014; 135:335-347.
77. Yap KL, Kiyotani K, Tamura K, Antic T, Jang M, Montoya M, Campanile A, Yew PY, Ganshert C, Fujioka T, Steinberg GD, O'Donnell PH, Nakamura Y. Whole-exome sequencing of muscle-invasive bladder cancer identifies recurrent mutations of UNC5C and prognostic importance of DNA repair gene mutations on survival. Clinical cancer research : an official journal of the American Association for Cancer Research. 2014; 20:6605-6617.
78. Nickerson ML, Dancik GM, Im KM, Edwards MG, Turan S, Brown J, Ruiz-Rodriguez C, Owens C, Costello JC, Guo G, Tsang SX, Li Y, Zhou Q, Cai Z, Moore LE, Lucia MS, et al. Concurrent alterations in TERT, KDM6A, and the BRCA pathway in bladder cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2014; 20:4935-4948.
79. Sun CH, Chang YH, Pan CC. Activation of the PI3K/Akt/mTOR pathway correlates with tumour progression and reduced survival in patients with urothelial carcinoma of the urinary bladder. Histopathology. 2011; 58:1054-1063.
80. Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. Nature reviews Molecular cell biology. 2014; 15:178-196.
81. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nature reviews Cancer. 2002; 2:442-454.
82. Gui Y, Guo G, Huang Y, Hu X, Tang A, Gao S, Wu R, Chen C, Li X, Zhou L, He M, Li Z, Sun X, Jia W, Chen J, Yang S, et al. Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder. Nature genetics. 2011; 43:875-878.
83. Wilson BG, Roberts CW. SWI/SNF nucleosome remodellers and cancer. Nature reviews Cancer. 2011; 11:481-492.
84. Roberts CW, Orkin SH. The SWI/SNF complex-chromatin and cancer. Nature reviews Cancer. 2004; 4:133-142.
85. Lei AQ, Cheng L, Pan CX. Current treatment of metastatic bladder cancer and future directions. Expert Review of Anticancer Therapy. 2011; 11:1851-1862.
86. Sternberg CN. Muscle invasive and metastatic bladder cancer. Annals of Oncology. 2006; 17:x23-x30.
87. Winquist E, Kirchner TS, Segal R, Chin J, Lukka H. Neoadjuvant chemotherapy for transitional cell carcinoma of the bladder: A systematic review and meta-analysis. Journal of Urology. 2004; 171:561-569.
88. Tanji N, Ozawa A, Miura N, Yanagihara Y, Sasaki T, Nishida T, Kikugawa T, Ikeda T, Ochi T, Shimamoto K, Aoki K, Yokoyama M. Long-term results of combined chemotherapy with gemcitabine and cisplatin for metastatic urothelial carcinomas. International Journal of Clinical Oncology. 2010; 15:369-375.
89. Saxman SB, Propert KJ, Einhorn LH, Crawford ED, Tannock I, Raghavan D, Loehrer PJ Sr, Trump D. Long- term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1997; 15:2564-2569.
90. Tomaszewski JJ, Smaldone MC. (2010) Emerging intravesical therapies for management of nonmuscle invasive bladder cancer. Open Access Journal of Urology. 2010; :67-84.
91. Babjuk M, Burger M, Zigeuner R, Shariat SF, Van Rhijn BWG, Compérat E, Sylvester RJ, Kaasinen E, Böhle A, Palou Redorta J, Rouprêt M. EAU guidelines on non-muscle-invasive Urothelial carcinoma of the bladder:Update (2013). European urology. 2013; 64:639-653.
92. Meyer JP, Persad R, Gillatt DA. Use of bacille Calmette-Guérin in superficial bladder cancer. Postgraduate Medical Journal. 2002; 78:449-454.
93. Mungan NA, Witjes JA. Bacille Calmette-Guérin in superficial transitional cell carcinoma. British Journal of Urology. 1998; 82:213-223.
94. Gontero P, Oderda M, Mehnert A, Gurioli A, Marson F, Lucca I, Rink M, Schmid M, Kluth LA, Pappagallo G, Sogni F, Sanguedolce F, Schiavina R, Martorana G, Shariat SF, Chun F. The impact of intravesical gemcitabine and 1/3 dose bacillus Calmette-Guérin instillation therapy on the quality of life in patients with nonmuscle invasive bladder cancer: Results of a prospective, randomized, phase II trial. Journal of Urology. 2013; 190:857-862.
95. Liu XD, AC, Patel P, Viney RP, Foster MC, Porfiri E, James ND, Bryan RT. Cytokines as effectors and predictors of responses in the treatment of bladder cancer by bacillus Calmette-Guerin. Future Oncology. 2014; 10:1443-1456.
96. Prescott S, Jackson AM, Hawkyard SJ, Alexandroff AB, James K. Mechanisms of action of intravesical bacille Calmette-Guérin: Local immune mechanisms. Clinical Infectious Diseases. 2000; 31:S91-S93.
97. Lamm DL. Efficacy and safety of bacille Calmette-Guérin immunotherapy in superficial bladder cancer. Clinical Infectious Diseases. 2000; 31:S86-S90.
98. Siddik ZH. Cisplatin: Mode of cytotoxic action and molecular basis of resistance. Oncogene. 2003; 22:7265-7279.
99. Jakse G, Hofstadter F. Mechanisms of action of intravesical treatment - Effect on the ABH surface antigens of urothelial cells. Cancer Chemotherapy and Pharmacology. 1983; 11:S74-S78.
100. Plunkett W, Huang P, Xu YZ, Heinemann V, Grunewald R, Gandhi V. Gemcitabine: Metabolism, mechanisms of action, and self-potentiation. Seminars in Oncology. 1995; 22:3-10.
101. James ND, Hussain SA, Hall E, Jenkins P, Tremlett J, Rawlings C, Crundwell M, Sizer B, Sreenivasan T, Hendron C, Lewis R, Waters R, Huddart RA. Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. New England Journal of Medicine. 2012; 366:1477-1488.
102. Tsang RY, Al-Fayea T, Au HJ. Cisplatin overdose:Toxicities and management. Drug Safety. 2009; 32:1109-1122.
103. Sternberg CN, Yagoda A, Scher HI, Watson RC, Ahmed T, Weiselberg LR, Geller N, Hollander PS, Herr HW, Sogani PC. Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium. Journal of Urology. 1985; 133:403-407.
104. Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O, Castedo M, Kroemer G. Molecular mechanisms of cisplatin resistance. Oncogene. 2012; 31:1869-1883.
105. Hurst CD, Knowles MA. Molecular subtyping of invasive bladder cancer: time to divide and rule?. Cancer cell. 2014; 25:135-136.
106. Galluzzi L, Vitale I, Michels J, Brenner C, Szabadkai G, Harel-Bellan A, Castedo M, Kroemer G. Systems biology of cisplatin resistance: past, present and future. Cell Death Dis. 2014; 5:e1257.
107. Choi W, Porten S, Kim S, Willis D, Plimack ER, Hoffman-Censits J, Roth B, Cheng T, Tran M, Lee IL, Melquist J, Bondaruk J, Majewski T, Zhang S, Pretzsch S, Baggerly K, et al. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer cell. 2014; 25:152-165.
108. Mitazaki S, Kato N, Suto M, Hiraiwa K, Abe S. Interleukin-6 deficiency accelerates cisplatin-induced acute renal failure but not systemic injury. Toxicology. 2009; 265:115-121.
109. Nicholson S. Chemotherapy for bladder cancer in patients with impaired renal function. Nature Reviews Urology. 2012; 9:52-57.
110. Redelman-Sidi G, Glickman MS, Bochner BH. The mechanism of action of BCG therapy for bladder cancer-A current perspective. Nature Reviews Urology. 2014; 11:153-162.
111. Chevalier MF, Nardelli-Haefliger D, Domingos-Pereira S, Jichlinski P, Derré L. Immunotherapeutic strategies for bladder cancer. Human Vaccines and Immunotherapeutics. 2014; 10:977-981.
112. Dhodapkar MV, Sznol M, Zhao B, Wang D, Carvajal RD, Keohan ML, Chuang E, Sanborn RE, Lutzky J, Powderly J, Kluger H, Tejwani S, Green J, Ramakrishna V, Crocker A, Vitale L, et al. Induction of antigen-specific immunity with a vaccine targeting NY-ESO-1 to the dendritic cell receptor DEC-205. Science Translational Medicine. 2014; 6.
113. Galsky MD, Hahn NM, Rosenberg J, Sonpavde G, Hutson T, Oh WK, Dreicer R, Vogelzang N, Sternberg CN, Bajorin DF, Bellmunt J. Treatment of patients with metastatic urothelial cancer "unfit" for Cisplatin-based chemotherapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011; 29:2432-2438.
114. Pruthi RS, Nielsen M, Heathcote S, Wallen EM, Rathmell WK, Godley P, Whang Y, Fielding J, Schultz H, Grigson G, Smith A, Kim W. A phase II trial of neoadjuvant erlotinib in patients with muscle-invasive bladder cancer undergoing radical cystectomy: clinical and pathological results. BJU international. 2010; 106:349-354.
115. Gallagher DJ, Milowsky MI, Gerst SR, Ishill N, Riches J, Regazzi A, Boyle MG, Trout A, Flaherty AM, Bajorin DF. Phase II study of sunitinib in patients with metastatic urothelial cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010; 28:1373-1379.
116. Grivas PD, Daignault S, Tagawa ST, Nanus DM, Stadler WM, Dreicer R, Kohli M, Petrylak DP, Vaughn DJ, Bylow KA, Wong SG, Sottnik JL, Keller ET, Al-Hawary M, Smith DC, Hussain M. Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma. Cancer. 2014; 120:692-701.
117. Sridhar SS, Winquist E, Eisen A, Hotte SJ, McWhirter E, Tannock IF, Mukherjee SD, Wang L, Blattler C, Wright JJ, Moore MJ. A phase II trial of sorafenib in first-line metastatic urothelial cancer: a study of the PMH Phase II Consortium. Investigational new drugs. 2011; 29:1045-1049.
118. Li Y, Yang X, Su LJ, Flaig TW. Pazopanib synergizes with docetaxel in the treatment of bladder cancer cells. Urology. 2011; 78:233. e237-213.
119. Pili R, Qin R, Flynn PJ, Picus J, Millward M, Ho WM, Pitot H, Tan W, Miles KM, Erlichman C, Vaishampayan U. A phase II safety and efficacy study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor pazopanib in patients with metastatic urothelial cancer. Clinical genitourinary cancer. 2013; 11:477-483.
120. Nicolle G, Daher A, Maille P, Vermey M, Loric S, Bakkar A, Wallerand H, Vordos D, Vacherot F, de Medina SG, Abbou CC, Van der Kwast T, Thiery JP, Radvanyi F, Chopin DK. Gefitinib inhibits the growth and invasion of urothelial carcinoma cell lines in which Akt and MAPK activation is dependent on constitutive epidermal growth factor receptor activation. Clinical cancer research : an official journal of the American Association for Cancer Research. 2006; 12:2937-2943.
121. Philips GK, Halabi S, Sanford BL, Bajorin D, Small EJ, Cancer B. A phase II trial of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial tract carcinoma: results of Cancer and Leukemia Group B (CALGB) 90102. Annals of oncology : official journal of the European Society for Medical Oncology /ESMO. 2009; 20:1074-1079.
122. Lamont FR, Tomlinson DC, Cooper PA, Shnyder SD, Chester JD, Knowles MA. Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo. British journal of cancer. 2011; 104:75-82.
123. Iyer G, Milowsky MI. Fibroblast growth factor receptor-3 in urothelial tumorigenesis. Urologic oncology. 2013; 31:303-311.
124. Petrylak DP, Tangen CM, Van Veldhuizen PJ, Jr., Goodwin JW, Twardowski PW, Atkins JN, Kakhil SR, Lange MK, Mansukhani M, Crawford ED. Results of the Southwest Oncology Group phase II evaluation (study S0031) of ZD1839 for advanced transitional cell carcinoma of the urothelium. BJU international. 2010; 105:317-321.
125. Hahn NM, Stadler WM, Zon RT, Waterhouse D, Picus J, Nattam S, Johnson CS, Perkins SM, Waddell MJ, Sweeney CJ, Hoosier Oncology G. Phase II trial of cisplatin, gemcitabine, and bevacizumab as first-line therapy for metastatic urothelial carcinoma: Hoosier Oncology Group GU 04-75. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011; 29:1525-1530.
126. Twardowski P, Stadler WM, Frankel P, Lara PN, Ruel C, Chatta G, Heath E, Quinn DI, Gandara DR. Phase II study of Aflibercept (VEGF-Trap) in patients with recurrent or metastatic urothelial cancer, a California Cancer Consortium Trial. Urology. 2010; 76:923-926.
127. Jimenez RE, Hussain M, Bianco FJ, Jr., Vaishampayan U, Tabazcka P, Sakr WA, Pontes JE, Wood DP Jr. Grignon DJ. Her-2/neu overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic significance and comparative analysis in primary and metastatic tumors. Clinical cancer research : an official journal of the American Association for Cancer Research. 2001; 7:2440-2447.
128. Marin AP, Arranz EE, Sanchez AR, Aunon PZ, Baron MG. Role of anti-Her-2 therapy in bladder carcinoma. Journal of cancer research and clinical oncology. 2010; 136:1915-1920.
129. Culine S, Sellam Z, Bouaita L, Assaf E, Delbaldo C, Verlinde-Carvalho M, Pouessel D. Combining paclitaxel and lapatinib as second-line treatment for patients with metastatic transitional cell carcinoma: a case series. Anticancer research. 2012; 32:3949-3952.
130. Makhlin I, Zhang J, Long CJ, Devarajan K, Zhou Y, Klein-Szanto AJ, Huang M, Chernoff J, Boorjian SA. The mTOR pathway affects proliferation and chemosensitivity of urothelial carcinoma cells and is upregulated in a subset of human bladder cancers. BJU international. 2011; 108:E84-90.
131. Mansure JJ, Nassim R, Chevalier S, Rocha J, Scarlata E, Kassouf W. Inhibition of mammalian target of rapamycin as a therapeutic strategy in the management of bladder cancer. Cancer biology & therapy. 2009; 8:2339-2347.
132. Pinto-Leite R, Arantes-Rodrigues R, Palmeira C, Colaco B, Lopes C, Colaco A, Costa C, da Silva VM, Oliveira P, Santos L. Everolimus combined with cisplatin has a potential role in treatment of urothelial bladder cancer. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2013; 67:116-121.
133. Milowsky MI, Iyer G, Regazzi AM, Al-Ahmadie H, Gerst SR, Ostrovnaya I, Gellert LL, Kaplan R, Garcia-Grossman IR, Pendse D, Balar AV, Flaherty AM, Trout A, Solit DB, Bajorin DF. Phase II study of everolimus in metastatic urothelial cancer. BJU international. 2013; 112:462-470.
134. Seront E, Rottey S, Sautois B, Kerger J, D'Hondt LA, Verschaeve V, Canon JL, Dopchie C, Vandenbulcke JM, Whenham N, Goeminne JC, Clausse M, Verhoeven D, Glorieux P, Branders S, Dupont P, et al. Phase II study of everolimus in patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract: clinical activity, molecular response, and biomarkers. Annals of oncology : official journal of the European Society for Medical Oncology /ESMO. 2012; 23:2663-2670.
135. Seront E, Pinto A, Bouzin C, Bertrand L, Machiels JP, Feron O. PTEN deficiency is associated with reduced sensitivity to mTOR inhibitor in human bladder cancer through the unhampered feedback loop driving PI3K/Akt activation. British journal of cancer. 2013; 109:1586-1592.
136. Hu XP, Ma LL, Wang Y, Yin H, Wang W, Yang XY, Zhang XD. Rapamycin instead of mycophenolate mofetil or azathioprine in treatment of post-renal transplantation urothelial carcinoma. Chinese medical journal. 2009; 122:35-38.
137. Wang SM, Tai HC, Chueh SC, Chung SD, Lai MK. Sirolimus does not absolutely abolish the occurrence/recurrence of urothelial carcinoma in renal transplant recipients. Transplantation proceedings. 2008; 40:2395-2396.
138. Gerullis H, Eimer C, Ecke TH, Georgas E, Freitas C, Kastenholz S, Arndt C, Heusch C, Otto T. A phase II trial of temsirolimus in second-line metastatic urothelial cancer. Medical oncology. 2012; 29:2870-2876.
139. Shah G, Zielonka J, Chen F, Zhang G, Cao Y, Kalyanaraman B, See W. H2O2 generation by bacillus Calmette-Guerin induces the cellular oxidative stress response required for bacillus Calmette-Guerin direct effects on urothelial carcinoma biology. The Journal of urology. 2014; 192:1238-1248.
140. Zhang G, Chen F, Cao Y, Amos JV, Shah G, See WA. HMGB1 release by urothelial carcinoma cells in response to Bacillus Calmette-Guerin functions as a paracrine factor to potentiate the direct cellular effects of Bacillus Calmette-Guerin. The Journal of urology. 2013; 190:1076-1082.
141. Malmstrom PU, Loskog AS, Lindqvist CA, Mangsbo SM, Fransson M, Wanders A, Gardmark T, Totterman TH. AdCD40L immunogene therapy for bladder carcinoma- the first phase I/IIa trial. Clinical cancer research : an official journal of the American Association for Cancer Research. 2010; 16:3279-3287.
142. Dyrskjot L, Zieger K, Kissow Lildal T, Reinert T, Gruselle O, Coche T, Borre M, Orntoft TF. Expression of MAGE-A3, NY-ESO-1, LAGE-1 and PRAME in urothelial carcinoma. British journal of cancer. 2012; 107:116-122.
143. Sharma P, Bajorin DF, Jungbluth AA, Herr H, Old LJ, Gnjatic S. Immune responses detected in urothelial carcinoma patients after vaccination with NY-ESO-1 protein plus BCG and GM-CSF. Journal of immunotherapy. 2008; 31:849-857.
144. Jana BR, Galsky MD, Hahn NM, Milowsky MI, Sonpavde G. Novel molecular targets for the therapy of urothelial carcinoma. Expert opinion on therapeutic targets. 2012; 16:499-513.
145. Sharma P, Shen Y, Wen S, Yamada S, Jungbluth AA, Gnjatic S, Bajorin DF, Reuter VE, Herr H, Old LJ, Sato E. CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma. Proceedings of the National Academy of Sciences of the United States of America. 2007; 104:3967-3972.
146. Baselga J, Swain SM. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nature reviews Cancer. 2009; 9:463-475.
147. Solit DB, Chiosis G. Development and application of Hsp90 inhibitors. Drug discovery today. 2008; 13:38-43.
148. Solit DB, Osman I, Polsky D, Panageas KS, Daud A, Goydos JS, Teitcher J, Wolchok JD, Germino FJ, Krown SE, Coit D, Rosen N, Chapman PB. Phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with metastatic melanoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2008; 14:8302-8307.
149. Socinski MA, Goldman J, El-Hariry I, Koczywas M, Vukovic V, Horn L, Paschold E, Salgia R, West H, Sequist LV, Bonomi P, Brahmer J, Chen LC, Sandler A, Belani CP, Webb T, et al. A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2013; 19:3068-3077.
150. Koga F, Tsutsumi S, Neckers LM. Low dose geldanamycin inhibits hepatocyte growth factor and hypoxia-stimulated invasion of cancer cells. Cell Cycle. 2007; 6:1393-1402.
151. Cheng HL, Trink B, Tzai TS, Liu HS, Chan SH, Ho CL, Sidransky D, Chow NH. Overexpression of c-met as a prognostic indicator for transitional cell carcinoma of the urinary bladder: A comparison with p53 nuclear accumulation. Journal of Clinical Oncology. 2002; 20:1544-1550.
152. Cheng HL, Liu HS, Lin YJ, Chen HHW, Hsu PY, Chang TY, Ho CL, Tzai TS, Chow NH. Co-expression of RON and MET is a prognostic indicator for patients with transitional-cell carcinoma of the bladder. British journal of cancer. 2005; 92:1906-1914.
153. Theodoropoulos VE, Lazaris AC, Sofras F, Gerzelis I, Tsoukala V, Ghikonti I, Manikas K, Kastriotis I. Hypoxia- inducible factor 1α expression correlates with angiogenesis and unfavorable prognosis in bladder cancer. European urology. 2004; 46:200-208.
154. Chai CY, Chen WT, Hung WC, Kang WY, Huang YC, Su YC, Yang CH. Hypoxia-inducible factor-1α expression correlates with focal macrophage infiltration, angiogenesis and unfavourable prognosis in urothelial carcinoma. Journal of Clinical Pathology. 2008; 61:658-664.
155. Lebret T, Watson RWG, Molinié V, O'Neill A, Gabriel C, Fitzpatrick JM, Botto H. Heat shock proteins HSP27, HSP60, HSP70, and HSP90: Expression in bladder carcinoma. Cancer. 2003; 98:970-977.
156. Yu HJ, Chang YH, Pan CC. Prognostic significance of heat shock proteins in urothelial carcinoma of the urinary bladder. Histopathology. 2013; 62:788-798.
157. Karkoulis PK, Stravopodis DJ, Margaritis LH, Voutsinas GE. 17-Allylamino-17-demethoxygeldanamycin induces downregulation of critical Hsp90 protein clients and results in cell cycle arrest and apoptosis of human urinary bladder cancer cells. BMC Cancer. 2010; 10:481.
158. Sato S, Fujita N, Tsuruo T. Modulation of Akt kinase activity by binding to Hsp90. Proceedings of the National Academy of Sciences of the United States of America. 2000; 97:10832-10837.
159. Barksdale KA, Bijur GN. The basal flux of Akt in the mitochondria is mediated by heat shock protein 90. Journal of Neurochemistry. 2009; 108:1289-1299.
160. Ma L, Sato F, Sato R, Matsubara T, Hirai K, Yamasaki M, Shin T, Shimada T, Nomura T, Mori K, Sumino Y, Mimata H. Dual targeting of heat shock proteins 90 and 70 promotes cell death and enhances the anticancer effect of chemotherapeutic agents in bladder cancer. Oncol Rep. 2014; 31:2482-2492.
161. Yoshida S, Koga F, Tatokoro M, Kawakami S, Fujii Y, Kumagai J, Neckers L, Kihara K. Low-dose Hsp90 inhibitors tumor-selectively sensitize bladder cancer cells to chemoradiotherapy. Cell Cycle. 2011; 10:4291-4299.
162. Acquaviva J, He S, Zhang C, Jimenez JP, Nagai M, Sang J, Sequeira M, Smith DL, Ogawa LS, Inoue T, Tatsuta N, Knowles MA, Bates RC, Proia DA. FGFR3 translocations in bladder cancer: differential sensitivity to HSP90 inhibition based on drug metabolism. Molecular cancer research : MCR. 2014; 12:1042-1054.
163. McDowell CL, Bryan Sutton R, Obermann WMJ. Expression of Hsp90 chaperome proteins in human tumor tissue. International Journal of Biological Macromolecules. 2009; 45:310-314.
164. Roh JL, Kim EH, Park HB, Park JY. The Hsp90 inhibitor 17-(allylamino)-17-demethoxygeldanamycin increases cisplatin antitumor activity by inducing p53-mediated apoptosis in head and neck cancer. Cell Death Dis. 2013; 4:e956.
165. McCollum AK, Lukasiewicz KB, TenEyck CJ, Lingle WL, Toft DO, Erlichman C. Cisplatin abrogates the geldanamycin- induced heat shock response. Molecular Cancer Therapeutics. 2008; 7:3256-3264.
166. Hubbard J, Erlichman C, Toft DO, Qin R, Stensgard BA, Felten S, Ten Eyck C, Batzel G, Ivy SP, Haluska P. Phase I study of 17-allylamino-17 demethoxygeldanamycin, gemcitabine and/or cisplatin in patients with refractory solid tumors. Investigational new drugs. 2011; 29:473-480.
167. Proia DA, Bates RC. Ganetespib and HSP90: Translating Preclinical Hypotheses into Clinical Promise. Cancer research. 2014; 74:1294-1300.
168. Machida H, Matsumoto Y, Shirai M, Kubota N. Geldanamycin, an inhibitor of Hsp90, sensitizes human tumour cells to radiation. International Journal of Radiation Biology. 2003; 79:973-980.
169. Dote H, Burgan WE, Camphausen K, Tofilon PJ. Inhibition of Hsp90 compromises the DNA damage response to radiation. Cancer research. 2006; 66:9211-9220.
170. Koll TT, Feis SS, Wright MH, Teniola MM, Richardson MM, Robles AI, Bradsher J, Capala J, Varticovski L. HSP90 inhibitor, DMAG, synergizes with radiation of lung cancer cells by interfering with base excision and ATM- mediated DNA repair. Molecular Cancer Therapeutics. 2008; 7:1985-1992.
171. Pos F, Remeijer P. Adaptive Management of Bladder Cancer Radiotherapy. Seminars in Radiation Oncology. 2010; 20:116-120.
172. Kabakov AE, Kudryavtsev VA, Gabai VL. Hsp90 inhibitors as promising agents for radiotherapy. Journal of Molecular Medicine. 2010; 88:241-247.
173. Kabakov AE, Kudryavtsev VA, Makarova YM. Inhibitors of heat shock protein 90 activity: A novel class of tumor radiosensitizers. Biophysics. 2011; 56:339-345.
174. Tatokoro M, Koga F, Yoshida S, Kawakami S, Fujii Y, Neckers L, Kihara K. Potential role of Hsp90 inhibitors in overcoming cisplatin resistance of bladder cancer-initiating cells. International journal of cancer Journal international du cancer. 2012; 131:987-996.
175. Koga F, Yoshida S, Tatokoro M, Kawakami S, Fujii Y, Kumagai J, Neckers L, Kihara K. ErbB2 and NFκB overexpression as predictors of chemoradiation resistance and putative targets to overcome resistance in Muscle-Invasive bladder cancer. PloS one. 2011; 6.
176. Guo F, Rocha K, Bali P, Pranpat M, Fiskus W, Boyapalle S, Kumaraswamy S, Balasis M, Greedy B, Armitage ESM, Lawrence N, Bhalla K. Abrogation of heat shock protein 70 induction as a strategy to increase antileukemia activity of heat shock protein 90 inhibitor 17-allylamino-demethoxy geldanamycin. Cancer research. 2005; 65:10536-10544.
177. Zaarur N, Gabai VL, Porco Jr JA, Calderwood S, Sherman MY. Targeting heat shock response to sensitize cancer cells to proteasome and Hsp90 inhibitors. Cancer research. 2006; 66:1783-1791.
178. Sato A, Asano T, Ito K, Asano T. 17-Allylamino-17- demethoxygeldanamycin and ritonavir inhibit renal cancer growth by inhibiting the expression of heat shock factor-1. International Journal of Oncology. 2012; 41:46-52.
179. Budina-Kolomets A, Balaburski GM, Bondar A, Beeharry N, Yen T, Murphy ME. Comparison of the activity of three different HSP70 inhibitors on apoptosis, cell cycle arrest, autophagy inhibition, and HSP90 inhibition. Cancer Biology and Therapy. 2014; 15:194-199.
180. McConnell JR, McAlpine SR. Heat shock proteins 27, 40, and 70 as combinational and dual therapeutic cancer targets. Bioorganic and Medicinal Chemistry Letters. 2013; 23:1923-1928.
181. Horne BE, Li T, Genevaux P, Georgopoulos C, Landry SJ. The Hsp40 J-domain stimulates Hsp70 when tethered by the client to the ATPase domain. Journal of Biological Chemistry. 2010; 285:21679-21688.
182. Lebret T, Watson RWG, Fitzpatrick JM. Heat shock proteins:Their role in urological tumors. Journal of Urology. 2003; 169:338-346.
183. Powers MV, Clarke PA, Workman P. Death by chaperone:HSP90, HSP70 or both? Cell Cycle. 2009; 8:518-526.
184. Acquaviva J, He S, Sang J, Smith DL, Sequeira M, Zhang C, Bates RC, Proia DA. mTOR inhibition potentiates HSP90 inhibitor activity via cessation of HSP synthesis. Molecular Cancer Research. 2014; 12:703-713.
185. Marcu MG, Chadli A, Bouhouche I, Catelli M, Neckers LM. The heat shock protein 90 antagonist novobiocin interacts with a previously unrecognized ATP-binding domain in the carboxyl terminus of the chaperone. The Journal of biological chemistry. 2000; 275:37181-37186.
186. Donnelly A, Blagg BSJ. Novobiocin and additional inhibitors of the Hsp90 C-terminal nucleotide-binding pocket. Current Medicinal Chemistry. 2008; 15:2702-2717.
187. Matts RL, Dixit A, Peterson LB, Sun L, Voruganti S, Kalyanaraman P, Hartson SD, Verkhivker GM, Blagg BSJ. Elucidation of the Hsp90 C-terminal inhibitor binding site. ACS Chemical Biology. 2011; 6:800-807.
188. Gavenonis J, Jonas NE, Kritzer JA. Potential C-terminaldomain inhibitors of heat shock protein 90 derived from a C-terminal peptide helix. Bioorganic and Medicinal Chemistry. 2014.
189. Yun SJ, Kim WJ. Role of the epithelial-mesenchymal transition in bladder cancer: from prognosis to therapeutic target. Korean journal of urology. 2013; 54:645-650.
190. Wang DS, Rieger-Christ K, Latini JM, Moinzadeh A, Stoffel J, Pezza JA, Saini K, Libertino JA, Summerhayes IC. Molecular analysis of PTEN and MXI1 in primary bladder carcinoma. International journal of cancer Journal international du cancer. 2000; 88:620-625.
191. Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer cell. 2007; 12:9-22.
192. Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell. 2006; 124:471-484.
193. Dreesen O, Brivanlou AH. Signaling pathways in cancer and embryonic stem cells. Stem cell reviews. 2007; 3:7-17.
194. Xia Y, Padre RC, De Mendoza TH, Bottero V, Tergaonkar VB, Verma IM. Phosphorylation of p53 by IkappaB kinase 2 promotes its degradation by beta-TrCP. Proceedings of the National Academy of Sciences of the United States of America. 2009; 106:2629-2634.
195. Schulz WA. Understanding urothelial carcinoma through cancer pathways. International journal of cancer Journal international du cancer. 2006; 119:1513-1518.